DAVENPORT & Co LLC trimmed its position in Sanofi (NASDAQ:SNY - Free Report) by 1.0% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 2,111,628 shares of the company's stock after selling 20,464 shares during the period. DAVENPORT & Co LLC owned about 0.09% of Sanofi worth $101,770,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Sanofi by 124.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company's stock valued at $1,344,000 after acquiring an additional 13,358 shares during the last quarter. Axxcess Wealth Management LLC boosted its stake in shares of Sanofi by 130.5% in the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company's stock valued at $568,000 after purchasing an additional 5,794 shares during the last quarter. Ballentine Partners LLC boosted its stake in shares of Sanofi by 68.7% in the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company's stock valued at $1,445,000 after purchasing an additional 10,617 shares during the last quarter. Voya Investment Management LLC grew its position in shares of Sanofi by 11.6% during the 1st quarter. Voya Investment Management LLC now owns 206,635 shares of the company's stock worth $11,460,000 after buying an additional 21,540 shares during the period. Finally, Sowell Financial Services LLC bought a new stake in shares of Sanofi during the first quarter worth approximately $328,000. Institutional investors own 14.04% of the company's stock.
Sanofi Stock Up 1.5%
NASDAQ:SNY opened at $50.90 on Monday. Sanofi has a 1 year low of $44.62 and a 1 year high of $60.12. The stock has a 50-day moving average price of $48.19 and a two-hundred day moving average price of $49.98. The stock has a market cap of $124.99 billion, a price-to-earnings ratio of 12.24, a PEG ratio of 1.24 and a beta of 0.51. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.
Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business had revenue of $11.34 billion for the quarter, compared to the consensus estimate of $9.91 billion. During the same quarter last year, the firm earned $1.73 EPS. The company's revenue for the quarter was down 7.0% on a year-over-year basis. As a group, equities analysts expect that Sanofi will post 4.36 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on the stock. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. JPMorgan Chase & Co. upgraded Sanofi from a "neutral" rating to an "overweight" rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a "hold" rating to a "buy" rating in a report on Tuesday, September 2nd. Weiss Ratings reissued a "hold (c)" rating on shares of Sanofi in a research note on Saturday, September 27th. Finally, Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $62.67.
Get Our Latest Report on Sanofi
About Sanofi
(
Free Report)
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Sanofi, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sanofi wasn't on the list.
While Sanofi currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
